Epsilon Healthcare Limited

ASX:EPN Voorraadrapport

Marktkapitalisatie: AU$7.2m

Epsilon Healthcare Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Epsilon Healthcare's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 16.1% per year.

Belangrijke informatie

-4.2%

Groei van de winst

9.1%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie31.2%
Inkomstengroei16.1%
Rendement op eigen vermogen-64.7%
Nettomarge-82.2%
Laatste winstupdate30 Jun 2023

Recente prestatie-updates uit het verleden

Recent updates

Does Epsilon Healthcare (ASX:EPN) Have A Healthy Balance Sheet?

Oct 13
Does Epsilon Healthcare (ASX:EPN) Have A Healthy Balance Sheet?

Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

Jun 30
Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

We Think Epsilon Healthcare (ASX:EPN) Has A Fair Chunk Of Debt

Sep 26
We Think Epsilon Healthcare (ASX:EPN) Has A Fair Chunk Of Debt

Is Epsilon Healthcare (ASX:EPN) Weighed On By Its Debt Load?

Jun 13
Is Epsilon Healthcare (ASX:EPN) Weighed On By Its Debt Load?

Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

Feb 27
Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

Opbrengsten en kosten

Hoe Epsilon Healthcare geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

ASX:EPN Opbrengsten, kosten en inkomsten (AUD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 237-650
31 Mar 237-1060
31 Dec 227-1360
30 Sep 226-1370
30 Jun 225-1370
31 Mar 225-1180
31 Dec 215-9100
30 Sep 216-9110
30 Jun 217-9120
31 Mar 217-10110
31 Dec 207-11110
30 Sep 207-11110
30 Jun 206-12110
31 Mar 205-12100
31 Dec 195-12100
30 Sep 194-1190
30 Jun 194-1190
31 Mar 193-1090
31 Dec 183-980
30 Sep 183-770
30 Jun 183-560
31 Mar 182-450
31 Dec 172-330

Kwaliteitswinsten: EPN is currently unprofitable.

Groeiende winstmarge: EPN is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: EPN is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.

Versnelling van de groei: Unable to compare EPN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: EPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).


Rendement op eigen vermogen

Hoge ROE: EPN has a negative Return on Equity (-64.69%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden